Biotech | April 06, 2022
MilliporeSigma acquires MAST platform from Lonza
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
The expansion makes Exothera one of the largest viral vector facilities in Europe
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The facility is expected to be completed in 2024
Subscribe To Our Newsletter & Stay Updated
